IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applic	ant: KIMCHY Yoav et al	§ §		
C . IN				
Serial No.:	10/616,301	§ § §		
Filed:	July 10, 2003	§ §	Group Art Unit: 3737	
For:	INGESTIBLE PILL FOR DIAGNOSING A GASTROINTESTINAL TRACT	\$ \$ \$	Attorney Docket: 25854	
Examiner:	CHAO Elmer M.	§		
Mail Stop An Commissione P.O. Box 145 Alexandria, V	er for Patents			
Sir:	SUPPLEMENTAL INFORMATION DISCLOSURE ST	ATE	<u>MENT</u>	
Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited, other than U.S. Patents and U.S. patent applications. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56, 37 CFR 1.97 and 37 CFR 1.98. The Examiner is requested to make these citations of official record in this application. The undersigned states:				
	CERTIFICATION OR FEE DUE			
This Information disclosure Statement is being filed within three months of filing a national application or entry of a national phase of an international application; or before the mailing date of a first Office action on the merits of the above-identified application. Accordingly, no fee or Certification is believed due. However, if a fee is due, authorization to deduct such fee from the Deposit Account 501407 of the undersigned is hereby provided.				
B. CER	TIFICATION (if appropriate)			
-	That each item of information contained in the information disclosure statement was first cited communication from a foreign patent office in a counterpart foreign application not more than three s prior to the filing of the information disclosure statement; or			
person signin information o	That no item of information contained in the information disclosure statement was cited in a munication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the son signing the certification after making reasonable inquiry, no item of information contained in the ormation disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three on the filing of the information disclosure statement.			
C. FEE	(if appropriate)			
	Please charge the fee of \$180 set forth in 37 CFR 1.17(p) to D	epos	it Account 501407.	
This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any one or more of the citations listed constitutes prior art.				

Respectfully submitted, /Jason H. Rosenblum/

Jason H. Rosenblum Registration No. 56437

Dated: 23 August 2010